Sutent
	Sutent
	Sutent
	Sutent
	Sutent
	Sutent
	Sutent
	Sutent
	Sutent
	Sutent
	Sutent

Sutent Drug Information

Sutentis an anti-neoplastic drug that is primarily indicated in the treatment of gastrointestinal stromal tumor, especially those cases where the treatment with imatinib has failed to yield positive results. It is also indicated in the treatment of renal cell carcinoma. This generic medication exerts its actions by inhibiting a substance called tyrosine kinase which is implicated in facilitating growth of the tumor and also in promoting metastasis or spread of the tumor. This medication is known to either stop the progression of the tumor or slow it down.

Sutent Dosage Information

The recommended dose of Sunitinib Malate for both, gastrointestinal stromal tumor and renal cell carcinoma is one oral dose of 50 mg every day for a duration of four weeks followed by two weeks off the drug. This is known as the 4/2 schedule. Physicians may feel the need to adjust the dose depending on each patient’s condition; this adjustment is usually 12.5 mg increase or decrease in dose. Discount Sutent may be purchased from North Meds in doses of 12.5 mg, 25 mg and 50 mg. Cheap Sutent is available at North Meds for the lowest of prices.

Side Effects and Precautions for Sutent

Commonly reported side effects after Sunitinib Malate use include asthenia, fatigue, nausea, vomiting, pain in the abdomen, dyspepsia, hypertension, impaired taste sensation, anorexia and stomatitis. Rarely, alopecia may also be noticed with the use of this drug. Patients with pancreatitis or liver impairment should withdraw from treatment with Sutent. Pregnant women must be particularly cautious while before they buy Sutent and use it as it can have serious detrimental effects on the developing fetus. If a patient on therapy with this drug becomes pregnant, the drug must be discontinued immediately. Also, nursing mother should refrain from consuming this formulation as it is not conclusively known whether it is excreted in breast milk.

* All trademarks and registered trademarks are the property of their respective owners.